Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation
Cancers · 09.11.2026 · 18 (21) · 3593
DOI: 10.3390/cancers18213593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 09.11.2026. Verfasst von Irene Graf und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (Germany).
Abstract (Originalsprache)
Background
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative option for patients with drug-refractory acute myeloid (AML) or acute lymphoblastic leukemia (ALL). Patients and Methods: We retrospectively analyzed 82 patients (median age 47.5 years, range 19–69; female:male ratio 1:1.28) with drug-refractory (R) or relapsed/refractory (RR) acute leukemia (AML n = 66; ALL n = 16) who were treated with clofarabine (10 mg/m2) and cyclophosphamide (200 mg/m2) days 1–4 (ClofCy) prior to HSCT.
Results
ClofCy resulted in rapid cytoreduction (median time to granulocytes
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
- Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
- Center for Public Health, Department of Environmental Health, Medical University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Irene Graf, Michael Kundi, Lina Z Rüsing, Peter Valent
Förderung
- Pfizer (Germany)
Zitieren
APA
Graf, I., Wohlfarth, P., Kundi, M., Mitterbauer, M., Schulenburg, A., Hauswirth, A. W., Gleixner, K. V., Knaus, H. A., Rüsing, L. Z., Rabitsch, W., Valent, P., & Sperr, W. R. (2026). Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation. Cancers, 18(21), 3593. https://doi.org/10.3390/cancers18213593
Vancouver
Graf I, Wohlfarth P, Kundi M, Mitterbauer M, Schulenburg A, Hauswirth AW, et al. Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation. Cancers. 2026;18(21):3593. doi:10.3390/cancers18213593
BibTeX
@article{Graf2026,
author = {Graf, Irene and Wohlfarth, Philipp and Kundi, Michael and Mitterbauer, Margit and Schulenburg, Axel and Hauswirth, Alexander W and Gleixner, Karoline V and Knaus, Hanna A and Rüsing, Lina Z and Rabitsch, Werner and Valent, Peter and Sperr, Wolfgang R},
title = {Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3593},
doi = {10.3390/cancers18213593}
}
EUVIMED